Literature DB >> 8798732

Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines.

M Borset1, E Lien, T Espevik, E Helseth, A Waage, A Sundan.   

Abstract

Myeloma cell line supernatants were screened for their ability to inhibit the activity of transforming growth factor-beta (TGFbeta) in the mink lung cell (Mv-1-Lu) bioassay. Supernatant from the human myeloma cell line JJN-3 contained potent TGFbeta antagonistic activity. This activity was isolated and found to be associated with a 72-78-kDa glycoprotein. Specific polyclonal and monoclonal antibodies were generated toward the 72-78-kDa protein, and these antibodies precipitated the TGFbeta inhibitory activity from JJN-3 supernatant. Upon amino acid sequencing the protein appeared to be identical to hepatocyte growth factor (HGF), and some of the generated antibodies directly blocked the action of recombinant HGF in various assays. By HGF-specific polymerase chain reaction we demonstrated that HGF mRNA was expressed in five out of five tested myeloma cell lines. The level of HGF protein in supernatants showed great variation from >500 ng/ml in JJN-3 supernatant to a few ng/ml in the supernatants from other myeloma cell lines. The same five cell lines were also screened for expression the HGF receptor c-MET. Four of them expressed the receptor as shown by reverse transcriptase-polymerase chain reaction and Western blot. The receptor was shown to be constitutively phosphorylated in the human myeloma cell line JJN-3. This receptor could be dephosphorylated by anti-HGF antibodies, indicating the existence of an autocrine HGF loop in this cell line. We propose that HGF/c-MET may play a role in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798732     DOI: 10.1074/jbc.271.40.24655

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.

Authors:  G Tsirakis; C A Pappa; F E Psarakis; M Fragioudaki; C Tsioutis; E Stavroulaki; A Boula; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.

Authors:  K Murakami; T Matsuura; M Sano; A Hashimoto; K Yonekura; R Sakukawa; Y Yamada; I Saiki
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

4.  Antiproliferation activities of NK4 on multiple myeloma.

Authors:  Wenzhong Que; Huili Liu; Qinqin Yang; Shanghua Xu
Journal:  Exp Ther Med       Date:  2018-08-22       Impact factor: 2.447

Review 5.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

Review 6.  Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.

Authors:  V Finisguerra; H Prenen; M Mazzone
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

Review 7.  Role of hepatocyte growth factor and its receptor c-met in multiple myeloma.

Authors:  C Seidel; M Børset; H Hjorth-Hansen; A Sundan; A Waage
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

8.  c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Authors:  Håkon Hov; Erming Tian; Toril Holien; Randi Utne Holt; Thea K Våtsveen; Unn-Merete Fagerli; Anders Waage; Magne Børset; Anders Sundan
Journal:  Eur J Haematol       Date:  2009-01-06       Impact factor: 2.997

9.  High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Authors:  Anne-Tove Brenne; Unn-Merete Fagerli; John D Shaughnessy; Thea Kristin Våtsveen; Torstein Baade Rø; Hanne Hella; Fenghuang Zhan; Bart Barlogie; Anders Sundan; Magne Børset; Anders Waage
Journal:  Eur J Haematol       Date:  2009-01-13       Impact factor: 2.997

10.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.